Editorial: Gastrointestinal Safety of COX-2 Selective and Nonselective NSAIDs-the Impact of the PRECISION Trial. Authors’ Reply

Alimentary Pharmacology and Therapeutics - United Kingdom
doi 10.1111/apt.14656
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Editorial: Gastrointestinal Safety of COX-2 Selective and Nonselective NSAIDs-the Impact of the PRECISION Trial

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Gastrointestinal Tolerability of the Selective Cyclooxygenase-2 (COX-2) Inhibitor Rofecoxib Compared With Nonselective COX-1 and COX-2 Inhibitors in Osteoarthritis

Archives of Internal Medicine
2000English

Risk of Gastrointestinal Effects With COX-2 Inhibitors and NSAIDs: How Strong Is the Evidence?

BMJ
2005English

Reduction in Cancer Risk by Selective and Nonselective Cyclooxygenase-2 (COX-2) Inhibitors

Journal of Experimental Pharmacology
Molecular MedicinePharmacology
2012English

Editorial: Lower Gastrointestinal Bleeding and Low-Dose Aspirin-Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

All-Cause Mortality of Elderly Australian Veterans Using COX-2 Selective or Non-Selective NSAIDs: A Longitudinal Study

British Journal of Clinical Pharmacology
Pharmacology
2010English

The KEYNOTE-061 Trial – Authors' Reply

The Lancet
Medicine
2019English

Questioning the Safety and Benefits of Evolocumab – Authors' Reply

The Lancet Diabetes and Endocrinology
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Editorial: The Impact of Steatosis on Liver Stiffness Quantification Is Minimal-Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy